Several clinical trials have been conducted with Bevacizumab (a monoclonal antibody that inhibits VEGF) as a monotherapy, and in one trial, the median overall survival was 9 months, however the combination of Bevacizumab and an immune checkpoint inhibitor (ipilimumab) displayed an overall survival rate of 25.1 months, highlighting the efficacy of combination therapies for melanoma in comparison to monotherapies [96,97]. This evidence concerns the gene VEGFA and melanoma.